Literature DB >> 14206919

PHASE II STUDIES OF HYDROXYUREA (NSC-32065) IN ADULTS: MULTIPLE MYELOMA AND LYMPHOMA.

P DAVIS.   

Abstract

Entities:  

Keywords:  ANTINEOPLASTIC AGENTS; DRUG THERAPY; HODGKIN'S DISEASE; LEUKOPENIA; MULTIPLE MYELOMA; SARCOMA, RETICULUM CELL; THROMBOPENIA; TOXICOLOGIC REPORT; UREA

Mesh：

Substances：

Year:  1964        PMID： 14206919

Source DB:  PubMed          Journal:  Cancer Chemother Rep        ISSN： 0069-0112


× No keyword cloud information.
  4 in total

1.  [Studies on the teratogenic effect of hydroxyurea during the early and embryonic development of mice].

Authors:  R Roll; F Bär
Journal:  Arch Toxikol       Date:  1969

2.  Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy.

Authors:  Marta Chesi; Geoffrey M Matthews; Victoria M Garbitt; Stephen E Palmer; Jake Shortt; Marcus Lefebure; A Keith Stewart; Ricky W Johnstone; P Leif Bergsagel
Journal:  Blood       Date:  2012-03-26       Impact factor: 22.113

3.  AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies.

Authors:  Marta Chesi; Davide F Robbiani; Michael Sebag; Wee Joo Chng; Maurizio Affer; Rodger Tiedemann; Riccardo Valdez; Stephen E Palmer; Stephanie S Haas; A Keith Stewart; Rafael Fonseca; Richard Kremer; Giorgio Cattoretti; P Leif Bergsagel
Journal:  Cancer Cell       Date:  2008-02       Impact factor: 31.743

Review 4.  Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy?

Authors:  Mukundan Baskar Mannargudi; Subrata Deb
Journal:  J Cancer Res Clin Oncol       Date:  2017-06-17       Impact factor: 4.322
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.